Back to results
US 2025/0019351 A1Published application
Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
AssigneePresident and Fellows of Harvard College
InventorsDavid D. Ginty, Lauren L. Orefice, Jinbo Lee
Life of this patent
Estimating the term…
Abstract
The present invention provides novel peripherally-restricted benzodiazepines with reduced blood brain barrier permeability and methods of use thereof for reducing tactile dysfunction, social impairment, and anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome.
Claims24
A compound having the structure of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- RA is RE, hydrogen, optionally substituted acyl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —ORD1, −N(RD1a)2, or —SRD1, wherein RD1 is independently selected from hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to an nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom;
- RB is RE, hydrogen, optionally substituted acyl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group;
- each instance of RC and RD is, independently, RE, hydrogen, halogen, nitro, optionally substituted acyl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —ORD1a, —N(RD1a)2, or —SRD1a, wherein RD1a is independently selected from hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to an nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom;
- X is O, NRF, or CHRF;
- p is 1, 2, 3, or 4;
- n is 1, 2, 3, 4, or 5;
- RE is a moiety that restricts the compound of Formula (I) to the peripheral nervous system, provided that the compound of Formula (I) comprises at least one RE;
- and
- RF is a nitrogen radical that combines with RB to form a fused 5-membered heterocyclyl or heteroaryl ring,
- wherein when RB is substituted heteroaliphatic, RC is hydrogen or halogen, RD is halogen, p is 1, and n is 1, RA is not hydrogen.
8 more elements
(canceled)
11-12. (canceled)
(canceled)
20-23. (canceled)
Dependencies are inferred from the claim text.